OTCPK:AROS.F

Stock Analysis Report

Executive Summary

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and commercialization of interspinous fusion systems and devices in Canada.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Aurora Spine is not covered by any analysts.

Share Price & News

How has Aurora Spine's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.0%

OTCPK:AROS.F

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

24.1%

OTCPK:AROS.F

8.7%

US Medical Equipment

1.7%

US Market

AROS.F outperformed the Medical Equipment industry which returned 8.7% over the past year.

AROS.F outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

AROS.FIndustryMarket
7 Day6.0%-1.2%1.2%
30 Day0.7%1.4%4.9%
90 Day-1.3%4.8%3.7%
1 Year24.1%24.1%9.6%8.7%3.9%1.7%
3 Year14.7%14.7%70.8%65.5%47.2%37.7%
5 Year-81.9%-81.9%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Aurora Spine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aurora Spine undervalued based on future cash flows and its price relative to the stock market?

5.15x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Aurora Spine's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Aurora Spine's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Aurora Spine is loss making, we can't compare its value to the US Medical Equipment industry average.

Aurora Spine is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aurora Spine, we can't assess if its growth is good value.


Price Based on Value of Assets

Aurora Spine is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Aurora Spine expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aurora Spine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aurora Spine performed over the past 5 years?

46.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aurora Spine does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Aurora Spine's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aurora Spine's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aurora Spine has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aurora Spine has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aurora Spine improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aurora Spine's financial position?


Financial Position Analysis

Aurora Spine is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aurora Spine's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Aurora Spine's level of debt (76.2%) compared to net worth is high (greater than 40%).

Unable to establish if Aurora Spine's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Aurora Spine has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Aurora Spine has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -73.4% per year.


Next Steps

Dividend

What is Aurora Spine's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aurora Spine's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aurora Spine's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aurora Spine has not reported any payouts.

Unable to verify if Aurora Spine's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aurora Spine has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aurora Spine's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average management tenure


CEO

Trent Northcutt (52yo)

7.6yrs

Tenure

US$157,045

Compensation

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. Mr. Northcutt served as Vice President at Spineart Inc. Prior to working for Spineart In ...


CEO Compensation Analysis

Trent's remuneration is lower than average for companies of similar size in United States of America.

Trent's compensation has increased whilst company is loss making.


Management Age and Tenure

6.7yrs

Average Tenure

The average tenure for the Aurora Spine management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.2yrs

Average Tenure

54.5yo

Average Age

The tenure for the Aurora Spine board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$23,54422 Oct 18
Laszlo Garamszegi
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares76,379
Max PriceUS$0.31

Ownership Breakdown


Management Team

  • Trent Northcutt (52yo)

    President

    • Tenure: 7.6yrs
    • Compensation: US$157.05k
  • Laszlo Garamszegi (48yo)

    Chief Technology Officer

    • Tenure: 6.7yrs
    • Compensation: US$151.07k
  • Dave Meyer

    VP, Chief Legal Officer & Secretary

    • Tenure: 0yrs
    • Compensation: US$143.07k
  • Sarina Mason

    Chief Financial Officer

    • Tenure: 2.6yrs
    • Compensation: US$151.36k

Board Members

  • David Rosenkrantz (61yo)

    Chairman

    • Tenure: 3.9yrs
    • Compensation: US$20.28k
  • Tracy Graf (55yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$2.02k
  • Joseph MacLellan (54yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$1.98k
  • Trent Northcutt (52yo)

    President

    • Tenure: 7.6yrs
    • Compensation: US$157.05k
  • Jim Snow (64yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$2.50k
  • Mike Seid (46yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$1.73k

Company Information

Aurora Spine Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aurora Spine Corporation
  • Ticker: AROS.F
  • Exchange: OTCPK
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$18.573m
  • Listing Market Cap: CA$14.004m
  • Shares outstanding: 46.43m
  • Website: https://www.aurora-spine.com

Location

  • Aurora Spine Corporation
  • 20 Holly Street
  • Suite 300
  • Toronto
  • Ontario
  • M4S 3B1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASGTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 2013
AROS.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2013

Biography

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and commercialization of interspinous fusion systems and devices in Canada. Its products include interspinou ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:14
End of Day Share Price2019/09/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.